Medical Cannabis is ‘Promising Treatment’ for Women Struggling to Reach Orgasm, Review Finds

A new review has found ‘consistent evidence’ that cannabis improves sexual function in women, and should be considered as a first-line treatment for patients with female orgasm disorder (FOD).

After reviewing findings from 16 peer-reviewed studies, including data from over 8,000 women, researchers have formally recommended that FOD be recognised as a qualifying condition for medical cannabis on prescription. Female Orgasmic Disorder (FOD), which is defined as a persistent or recurrent delay or absence of orgasm following sexual stimulation now affects up to 72% of premenopausal women, a sharp rise from 42% reported in 2013 by the DSM-5.  Experts say with this increasing prevalence over the last decade, FOD poses a ‘substantial public health concern’, especially given the negative impact on women’s lives, and say there is ‘growing need’ for policy to recognise the condition worthy of treatment, research, and care. According to the paper, women reporting FOD/difficulty demonstrate higher rates of mental health conditions, including anxiety and depression, post-traumatic stress disorder and increased use of prescription medications. Despite this, no treatments have been approved by the US Food and Drug Administration specifically to treat FOD and research and innovation into potential therapeutic approaches is said to be lacking.  READ MORE: Could cannabis help women reach orgasm? A new study says so The systematic review found that improved orgasm function, including increased frequency, intensity, quality, ease, satisfaction, and the ability to experience multiple orgasms per sexual encounter, was reported in all nine studies that evaluated cannabis use before sexual activity. “Cannabis appears to be a promising treatment for FOD/difficulty, with the majority of studies reviewed reporting improvements in orgasm function and satisfaction among women who use cannabis,” the authors state. “These benefits were observed across diverse study designs, populations, and cannabis use contexts. Given this growing body of evidence, FOD/difficulty should be considered a qualifying condition for medical cannabis, and medical cannabis should be evaluated as a potential first-line treatment.” In 2024, results from the first RCT examining the effects of cannabis on sexual function in women, demonstrated statistically significant improvements in orgasm function among gynaecological cancer patients using cannabis-infused vaginal suppositories. While the findings suggest a strong association between cannabis use and improved orgasm function, further RCTs are needed, the authors say, to ‘establish causality’ and better understand the impact of dosage, timing, route of administration, and specific strains on FOD-related symptoms. To date, three US states, Illinois, Connecticut and New Mexico, have approved FOD as a qualifying condition for medical cannabis, while Oregon will hold a public appeal to reconsider a petition in October.  Dr Suzanne Mulvehill, Clinical Sexologist and Founder of the Women’s Cannabis Project and Female Orgasm Research Institute, is leading the advocacy initiative to see FOD approved as a condition of treatment with medical cannabis in other jurisdictions, including the UK. “Recognising Female Orgasmic Disorder (FOD) in medical cannabis policy is both a public health imperative and a cultural reckoning,” she commented. “It affirms that women’s sexual health is important and worthy of treatment.”

New analysis has found that NHS access to medical cannabis could boost the UK’s economy by £13.3 billion over the next decade by returning thousands back to work.

Widening NHS access to medical cannabis could add £4.5 billion to the economy over five years, and £13.3 billion over a decade, according to an economic analysis by the Centre for Economics and Business Research (Cebr). The research, commissioned by Curaleaf Clinic, also suggests NHS access could help thousands of people with long-term health conditions return to work, while reducing hospital admissions for those eligible by 28% a year. Since its legalisation in 2018, private prescriptions for cannabis-based medicines have already contributed around £283 million in Gross Value Added (GVA) by helping people get well and back to work. Roughly 2.8 million people in the UK are currently locked out of employment due to long-term illness2. Polling3 conducted alongside the Cebr study, found 62% of those who have been out of work and prescribed medication believe they have exhausted all traditional treatment options. Those behind the research say the findings reveal a missed opportunity to improve lives, relieve pressure on the NHS, and support the government’s five-year plan to get more people working. “Our analysis shows that appropriately prescribed medical cannabis can help people with chronic conditions return to work,” commented Pushpin Singh, Managing Economist at the Centre for Economics and Business Research. “Expanding NHS access would benefit patients while delivering significant productivity gains and cost savings to the UK economy.” READ MORE: Economic analysis finds medical cannabis could save NHS £4 billion each year

Out of work and out of options

Many people who have experienced unemployment due to long-term illness are frustrated with traditional medications. In total, 55% who have been prescribed medication report they provide little relief and 48% say they negatively affect their quality of life. Being excluded from the workforce also takes a heavy emotional toll. Over half report a loss of self-esteem (56%) and declining confidence (52%), while 46% feel helpless. Mental health is also affected, with 47% saying unemployment has harmed their wellbeing and 39% experiencing feelings of embarrassment. Fatma Mehmet, a patient at Curaleaf Clinic, says medical cannabis has helped her regain her independence. “Living with chronic pain took a huge toll on my physical and mental health. As someone independent and career-driven, not being able to get out of bed and go to work made me feel as if my identity was being stripped away,” she says. “When I felt like I was at rock bottom and out of options, I discovered medical cannabis. I now have the ability to work, lead a team, and regain my independence. Expanding medical cannabis via the NHS would mean greater choice for more people, which can only be a good thing.”

A roadmap towards improving access 

However, there is interest in medical cannabis as an alternative therapy with nearly half (44%) who have not previously been prescribed it saying they would consider trying it if it were more widely available on the NHS. Nearly two-thirds of UK adults (64%) believe people with chronic ill-health should have more treatment options to get back to work, while 71% of those directly affected say medical cannabis should be made more widely available if it can help. But 40% of those who have struggled with employment due to a diagnosed long-term health condition are still unaware that medical cannabis is a legally available treatment in the UK, and 33% describe the current system as confusing, inaccessible or unclear. “As a doctor, I see daily how chronic illness doesn’t just affect someone’s health – it removes them from the workforce, creates economic hardship, and leads to a cascade of social and psychological problems that can worsen the cycle of ill health,” says Dr Simon Erridge, Director of Research at Curaleaf Clinic. “This analysis shows that medical cannabis isn’t just a health issue – it’s an economic one too. Our goal is to give people affected by poor health more choice and control in their treatment, helping them build independence and, where appropriate, re-enter the workplace. This report highlights a way forward. “We urgently need a roadmap towards improving access to medical cannabis via the NHS for suitable patients,  with the required investment in essential research to deliver this.”

---

Cannabis Health Symposium 2025 – advancing clinical practice in CBMPs

As patient access grows and prescribing frameworks evolve, health professionals need up-to-date, evidence-based guidance. The Cannabis Health Symposium 2025 brings together clinicians, prescribers, pharmacists, and researchers to explore the latest clinical evidence, policy updates, and real-world applications of cannabis-based medicines. What to expect:

• Evidence-led sessions on prescribing, safety, and efficacy
• Policy and regulatory updates for UK healthcare settings
• Practical insights from frontline clinicians and researchers
• Networking with peers, prescribers, and industry leaders

Join us in London for a day of clinical education and discussion on the future of cannabis in healthcare.